DRY EYE SYNDROME TREATMENT MARKET ANALYSIS
Global Dry Eye Syndrome Treatment Market: Key Developments
In February 2021, Mitotech, SA, a Luxembourg-based single-molecule biotechnology company, in collaboration with Essex Bio-Technology Limited, a bio-pharmaceutical company announce the result of phase 3 clinical study of SkQ1 as a treatment for Dry Eye Disease (DED).The clinical study clearly indicate significant impact of SkQ1on central corneal staining, that is further supported by improvement in visual function to patients suffering from dry eye.
In August 2021, AFT Pharmaceuticals, a specialty pharmaceutical company, provided a clinical study data according to which NovaTears+Omega-3, indicated for dry eye treatment, shows significantly effective treatment for evaporative Dry Eye Disease. The Meibomian Gland Assessment (MGD) score was taken which was improved from an entry level score of 7.1 to 3.0 (p<0.0001) over the course of the study. The latter result supports the hypothesis that the treatment might liquify meibum secretion excreted from the meibomian glands.
Dry Eye Syndrome Treatment Market Report Snapshots
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWant to Buy a Report but have a Limited Budget?
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :